News und Analysen
EQS-News: Abivax reports 2023 financial results and operational update
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological
Agilent Launches New Advanced Dilution System to Increase Lab Efficiency
Agilent Technologies Inc. (NYSE: A) today announced the launch of the Advanced Dilution System, the ADS 2, a new automation workflow solution that will increase productivity, lower cost of
Novocure to Report First Quarter 2024 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will
Poxel to Report Its 2023 Annual Results by the End of April 2024
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Klinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem Lungenkrebs
Novocure (NASDAQ: NVCR) gab heute bekannt, dass die klinische Phase-3-Studie METIS ihren primären Endpunkt erreicht hat und eine statistisch signifikante Verbesserung der Zeit bis zur
Acadia Healthcare Acquires Three Comprehensive Treatment Centers in North Carolina
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has recently completed the acquisitions of three comprehensive treatment centers (“CTC”) in North Carolina.
Two of the
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for
Resolutions of the Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.
ICON plc Schedules First Quarter 2024 Earnings Conference Call
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the first quarter 2024 after the
Inogen To Present at 23rd Annual Needham Virtual Healthcare Conference
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced management will participate in the 23rd Annual
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
On March 21
GenSight Biologics Reports Full Year 2023 Consolidated Financial Results
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the
EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
LivaNova to Announce First-Quarter 2024 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m. London time (8
EQS-News: Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply
EQS-News: Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply
Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report second quarter fiscal 2024 financial results after the market close on Wednesday, April 3, 2024.
Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Wednesday, May 1, 2024. The purpose